| | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H16N2OS |
| Molar mass | 284.38 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Dacemazine (INN, also known as Ahistan and Histantine) [1] is a phenothiazine derivative which acts as a histamine antagonist at the H1 subtype. First described in 1951, it was never marketed as a drug on its own, although a combination of dacemazine and di-tert-butylnaphthalenesulfonate was sold as an antispasmodic and antitussive under the trade name Codopectyl. [1] It was also assessed as a possible anticancer drug. [2]
Amide formation between phenothiazine (1) and chloroacetyl chloride (2) gives 10-(chloroacetyl)-phenothiazine (3). The subsequent displacement of the remaining halogen with dimethylamine (4) completes the synthesis of dacemazine (5).
| H1 |
| ||||
|---|---|---|---|---|---|
| H2 |
| ||||
| H3 |
| ||||
| H4 |
| ||||
| Classes | |
|---|---|
| Antidepressants (Tricyclic antidepressants (TCAs)) |
|
| Antihistamines |
|
| Antipsychotics |
|
| Anticonvulsants | |
| Anticholinergics | |
| Others | |